LRVHealth

In a recent Modern Healthcare?article, Brock E.W. Turner?discusses the challenges facing #digitalhealth companies preparing for IPOs in 2025. LRVHealth Managing Partner Keith J. Figlioli?shares his insights on how improving macroeconomic conditions could influence the push for these companies to go public.? ? Read the full article here: https://lnkd.in/eu9XzYKE

Next week, LRVHealth Managing Partner Josh Flum, will be moderating a panel discussion at HLTH USA. He will be joined by an incredible lineup of panelists including Rick Gates, SVP and Chief Pharmacy Officer, Walgreens; Laura Jensen, Head of Manufacturer & Prescriber Business Development, Amazon Pharmacy; and Lori Reilly, Chief Operating Officer, PhRMA.? ?? ?? Date: Monday, October 21? ?? Time: 1:30 PM – 2:10 PM PDT? ?? Location: Bold Stage? ?? Today, patients, payers, providers, and manufacturers all experience frustrations with the current drug channel. This panel will bring together experts from various perspectives to examine key challenges and explore how stakeholders can play a part in redesigning the system—improving access and aligning incentives more effectively for everyone involved.? ?? #HLTHUSA #healthinnovation #futureofhealth?

We had a great time connecting with industry leaders and innovators at the Behavioral Health Business INVEST 2024 conference this week! Behavioral Health Business, thank you for bringing together operators, investors, and thought leaders to explore the future of behavioral health!?? ? Ellen Herlacher took the stage alongside Within Health CEO, Wendy Oliver-Pyatt, and I Am Boundless, Inc. CEO, Patrick Maynard, PhD for a panel focused on diversification strategies for autism treatment providers.??

Ellen Herlacher is heading to Dallas next week to speak at the Behavioral Health Business INVEST conference to share her expertise on autism treatment. She’ll be joining Within Health CEO, Wendy Oliver-Pyatt, and I Am Boundless, Inc. CEO, Patrick Maynard, PhD on a panel titled, “Branching Out: Diversification Strategies for Autism Treatment Providers.” https://lnkd.in/gMyib-_V

With the U.S. election less than two months away, Julie Barnes, founder and CEO of Maverick Health Policy, is kicking off a series of Healthcare is Hard episodes that will explore the implications of the shifting power structure in Washington. During the next few podcast episodes – both before and after votes are cast – Keith J. Figlioli’s guests will help analyze how these changes will impact health policy and healthcare investing in public and private markets A few of the topics Keith and Julie discussed in the first episode include: - The alphabet soup of healthcare policy. One of the things that surprises Julie’s clients the most is the myriad of federal agencies that play a role overseeing healthcare – from HHS and CMS, to the FDA, CDC, NIH, FTC, NIST and many others beyond the big, well known organizations. With Healthcare accounting for nearly one quarter of the federal budget, there is a massive public sector infrastructure behind it, which is a big reason why healthcare policy takes so much effort to navigate. Julie offers advice for organizations looking to better understand healthcare policy, and for the people driving it. For example, she says the wonks, lawyers and lobbyists all talk funny. She admits to being part of this group, and says they need to reduce the lingo for the sake of those not so intimately involved. - AI changing everything. When discussing the modernization of the healthcare system, Julie talks about artificial intelligence (AI) being the main focus right now. She believes it has the potential to dramatically change everything because of the far-reaching impact it could have on areas ranging from workforce shortages to clinical decision support, user experiences for providers and patients, and more. She says healthcare AI policy can’t be written fast enough because of the speed with which the technology is developing, but there are many problems to navigate. One is that the public sector lacks experts who fundamentally understand this new technology, which will create challenges with ensuring that regulations are thoughtful enough to create a level of trust around AI without grinding innovation to a halt. - White House hysteria. While the country is fixated and divided on an historical race for the Presidency and the impacts of the outcome, Julie is quick to point out that changes in healthcare policy will not be fast, and will not be sweeping. There are broad brush policy changes you can expect based on party philosophies, like Democrats being more skeptical about the influence of private money than Republicans. But major legislative changes require bipartisan effort, no matter who controls the White House, Senate, and/or House. But one major area where Julie thinks many people are underestimating the potential for change is the impact of the Supreme Court’s recent decision on the Chevron Doctrine. She talks about how this will open the floodgates on a wave of litigation. Find the link in the comments!

Big thanks to everyone who joined us last night at The Twelve Thirty Club in Nashville! We had a blast hosting a rooftop reception with Andreessen Horowitz, Martin Ventures, and Frist Cressey Ventures, bringing together healthcare leaders, innovators, and investors after the first day of Health Evolution Connect!?? ?? Ellen Herlacher Devin Carty Marina Kusserow Caroline Young Tripp Peake Keith J. Figlioli Josh Flum?

Every major sector of the economy has independent entities that test and evaluate their products for safety. But nothing like that exist yet for #healthcare #AI, and that’s why Brian Anderson, MD helped found the Coalition for Health AI (CHAI). If you missed the #HealthcareIsHard podcast episode with Dr. Anderson, here’s a quick clip of his conversation with Keith J. Figlioli where he talked about what keeps him up at night and the need for AI assurance labs in healthcare. You can catch the full episode here: https://lnkd.in/eEmhP3RW

The infusion market is going through major changes, introducing new challenges and complexities. This shift also brings opportunities for providers who administer infusion drugs, patients who need those drugs, and payers who manage drug benefits. ? Infusion services represent a ~$120B+ market in the U.S. as of 2022, making up a sizeable and growing portion of medical drug spend. This is expected to grow by a CAGR of about 8-10% by 2026, driven by an expanding pipeline of infusible drugs as well as an increasing demand from an aging population. As the use of infusible drugs increases, payers are increasingly implementing site-of-care strategies to shift these services to lower-cost settings, i.e., from hospital outpatient departments (HOPD) to ambulatory settings. ? This raises the question: How will the landscape for infusion services evolve and how can different stakeholders participate in this shift? Read the full piece with insights from Josh Flum, Lise Courtney D'Amico, MBA, and Karen Au Yeung: https://lnkd.in/ejKNGDu5 If you are innovating in the infusion space, or if you’d like to discuss this topic with us further, we’d love to talk to you. Email us at [email protected].

Technology has not transformed healthcare. Will that change with AI? Keith J. Figlioli answered that question during his keynote at the #FHIRDevDays conference this summer. He looked back at the foundation the #HealthcareIT industry has laid over the past decade to support the current wave of innovation, and talked about how it will take the next decade to truly realize the value of #AI in #Healthcare. Thanks to Firely for organizing this valuable event and sharing the video for all to see! https://lnkd.in/emf_U7zd